Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening

By LabMedica International staff writers
Posted on 18 Nov 2026

Lung cancer screening can detect stage 1 disease, but false-positive findings, repeated follow-up, and radiation exposure remain important concerns. More...

Current NHS screening is limited to current and former smokers because of these risk-benefit considerations, leaving some never-smokers outside existing eligibility criteria. Blood-based biomarkers could help distinguish cancer-associated signals from normal biological variation and potentially refine early detection.

Researchers at the Cancer Research UK National Biomarker Centre are developing an artificial intelligence-based approach to support lung cancer screening through blood analysis. The work focuses on liquid biopsy markers, including molecules and cells released by early tumors into the bloodstream. By identifying molecular signatures associated with early disease, the researchers aim to complement CT screening and improve the accuracy of lung cancer detection.

The team is using a multimodal strategy rather than relying on a single type of measurement. Proteomic analysis is being used to measure thousands of circulating proteins, while circulating DNA fragments are being assessed for cancer-associated mutations, chemical modifications such as methylation, and differences in fragment size known as fragmentomics. Researchers are also examining rare abnormal circulating cells, including cancer cells, and collaborating with U.S. investigators to analyze circulating RNA.

The study uses 200 matched pairs of blood samples drawn from a larger lung screening collection. Each cancer-positive sample is paired with a sample from a participant who remained cancer-free but was otherwise similar in age, sex, and smoking history. Artificial intelligence models will be trained using the first 100 cancer-positive and matched-negative pairs and then tested on the remaining 100 pairs without being told which samples came from participants with cancer. The researchers will also determine the minimum number of measurements needed to maintain accuracy across these large, multimodal datasets.

The work is being conducted with Wythenshawe Hospital, the Christie Hospital, wider NHS trusts, collaborators in the U.S., and Cancer Research Horizons. If the data are convincing, the next step described by the team would be a much larger study. No diagnostic performance metrics have yet been reported.

“I'm hugely grateful that Cancer Research UK has given me a stable base to develop strong networks, not only in Manchester with the Christie Hospital and wider NHS trusts, but around the UK and abroad. We've got the right ingredients in the pot—now we're just going to have to see what these precious samples can tell us,” said Professor Caroline Dive CBE, center director at the Cancer Research UK National Biomarker Centre.

Related Links
Cancer Research UK National Biomarker Centre


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.